ANABV (ANABV) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-29

Key Insights

Director Susannah Gray received 11,250 restricted stock units (RSUs) on April 27, 2026, representing a standard equity compensation arrangement rather than insider buying activity.
The RSUs vest over approximately 3 years with 1/3 vesting on April 27, 2027 and the remaining 2/3 in equal annual installments, contingent on continued service to the company.
This is a routine equity grant to a board member with no market purchase involved (grant price of $0), indicating normal director compensation practices rather than a significant market signal about company prospects.

Want the newest filings?

This analysis covers the filing from 2026-04-29. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-22

AnaptysBio completed a spin-off of First Tracks Biotherapeutics on April 20, 2026, distributing 100 shares of First Tracks common stock to AnaptysBio shareholders, representing a corporate restructuring event.
The reporting person is listed as AnaptysBio, Inc. (the parent company) rather than an individual insider, indicating this Form 4 documents the organizational transaction rather than a traditional insider trading activity.
After the spin-off, the beneficial ownership shown is 0 shares of First Tracks for AnaptysBio, suggesting complete divestiture of the subsidiary through the distribution to shareholders.

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.